AIM
PTCT icon

Advyzon Investment Management’s PTC Therapeutics PTCT Stock Holding History

Advyzon Investment Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,533
Closed -$241K – 793
2026
Q1 		$241K Sell
3,533
-10
-0.3% -$708 0.02% 612
2025
Q4 		$269K Buy
+3,543
New +$257K 0.03% 470

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Advyzon Investment Management's PTCT Position: Q2 2026 in Review

Advyzon Investment Management sold out of PTC Therapeutics (PTCT) in Q2 2026, closing a stake of 3,533 shares — an estimated $241K sold.

Advyzon Investment Management first reported a position in PTCT in Q4 2025 and held it in 2 quarters. The position peaked at $269K in Q4 2025. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Advyzon Investment Management reported no remaining PTC Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Advyzon Investment Management sold 3,533 PTC Therapeutics shares in Q2 2026, an estimated $241K.
  • Advyzon Investment Management first reported a position in PTC Therapeutics in Q4 2025 and held it in 2 quarters.
  • Advyzon Investment Management's PTC Therapeutics position peaked at $269K in Q4 2025.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Advyzon Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.